Home Biosimilar Antibodies Protein Tyrosine Kinase CCK receptor Cofetuzumab (Anti-PTK7 / CCK4)
For research use only. Not for use in humans.

Cofetuzumab (Anti-PTK7 / CCK4)

Cofetuzumab (Anti-PTK7 / CCK4) is humanized IgG1 monoclonal antibody against protein tyrosine kinase 7 (PTK7) with potential antitumor activity. MW : 146.7 KD.

Cofetuzumab (Anti-PTK7 / CCK4)

Quality Control

Batch: A280301 Purity: 99% Protein concentration: 6.05mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CCKB
Nastorazepide 0
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Cofetuzumab (Anti-PTK7 / CCK4) is humanized IgG1 monoclonal antibody against protein tyrosine kinase 7 (PTK7) with potential antitumor activity. MW : 146.7 KD.
References

Product Details

CAS No. 1869928-62-0
Molecular Weight 146.7
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04189614 TERMINATED Drug: Cofetuzumab Pelidotin Cancer; Non-small Cell Lung Cancer (NSCLC) AbbVie 2020-02-13 PHASE1
NCT03904576 COMPLETED Drug: BI 1358894|Drug: Placebo Healthy Boehringer Ingelheim 2019-04-18 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-06-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.